Workshop for implementing support tools to promote safety in the prescribing of oral contraceptives

摘要 我们于2022年9月开始的谓词SBIR第一阶段拨款的总体目标是 调查药剂师使用我们专有的OvaryIt软件开出避孕药的可行性。 许多州允许药剂师开出避孕药方，但目前纸质的流程效率很低 对于忙碌的药剂师来说，很难融入到日常实践中。因此，尽管许多药剂师 有资格开避孕药的人很少，积极提供这些服务的人很少。继续有一种 美国对获得避孕服务的持续需求，约有1900万 生活在被认为是避孕沙漠的妇女。因为90%的人口居住在5英里以内 药房、药剂师处方的避孕服务有可能极大地增加获得避孕服务的机会 关爱，减少卫生保健系统中的不平等，并与妇女的高意外怀孕率作斗争 我们。 在第一阶段，OvaryIt团队已经开始与许多具有不同背景的药剂师建立联系 从美国各地收集见解和数据。除了主要的可行性目标外，该团队还有 聘请主题专家协助制定全面的实施一揽子计划， 解决采用药剂师处方避孕服务的障碍，确定 成功将解决方案整合到现有解决方案所需的技术和运营要求 药房工作流程，并进行可用性测试，以指导OvaryIt软件的渐进式改进。 早期的发现支持我们的假设，即药剂师对提供避孕服务感兴趣，并且 他们认为，使用OvaryIt软件可以提高效率、患者安全，并提高 将避孕服务纳入日常实践。此外，我们还收到了关于以下方面的宝贵反馈 对用户界面的潜在修改将指导未来系统的改进。 OvaryIt，LLC组建了一支强大的团队，拥有项目管理、避孕药物和 医疗技术的设计与实施。所有三名成员都承诺遵守以下时间要求 这个项目。OvaryIt团队愿意修改、调整和完善整体商业化战略 基于在i-Corps计划期间获得的知识。

SUMMARY The overall objective of our predicate SBIR Phase I grant, which commenced in September 2022, is to investigate the feasibility of pharmacists utilizing our proprietary OvaryIt software to prescribe contraceptives. Many states allow pharmacists to prescribe contraception, but the current paper-based process is inefficient and difficult to incorporate into daily practice for busy pharmacists. Therefore, even though many pharmacists are eligible to prescribe contraceptives, very few are actively offering these services. There continues to be an ongoing need for access to contraceptive services in the United States (US), with approximately 19 million women living in what is deemed a contraceptive desert. Because 90% of the population lives within 5 miles of a pharmacy, pharmacist-prescribed contraceptive services have the potential to dramatically increase access to care, decrease inequities in the health care system, and combat the high unintended pregnancy rate in the US. During Phase I, the OvaryIt Team has begun networking with numerous pharmacists with diverse backgrounds from across the US to gather insights and data. In addition to the primary feasibility objective, the team has recruited subject matter experts to assist in the creation of a comprehensive implementation package that addresses the barriers to the adoption of pharmacist-prescribed contraceptive services, determine the technological and operational requirements needed to successfully incorporate the solution into existing pharmacy workflows, and conduct usability testing to guide incremental improvements to the OvaryIt software. Early findings support our hypothesis that pharmacists are interested in providing contraceptive services, and they perceive that utilizing the OvaryIt software increases efficiency, patient safety, and the feasibility of incorporating contraceptive services into daily practice. Additionally, we received valuable feedback regarding potential modifications to the user interface that will guide improvements in the future system. OvaryIt, LLC has assembled a strong team with expertise in project management, contraceptive medicine, and medical technology design and implementation. All three members are committed to the time requirements of the program. The OvaryIt Team is willing to modify, adapt, and refine the overall commercialization strategy based on knowledge gained during the I-Corps Program.